BioCentury
ARTICLE | Clinical News

Enbrel etanercept: Enrolled Phase III trials

August 21, 2000 7:00 AM UTC

Immunex Corp. (IMNX), Seattle, Wash. Product: Enbrel etanercept Business: Cardiovascular Therapeutic category: Immune modulation Target: TNF Description: Recombinant p75 TNF receptor linked to the Fc...